- Home
- KG vs INKT Comparison
KG vs INKT Comparison
Compare KG & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KG | INKT |
|---|---|---|
| Founded | N/A | 2017 |
| Country | Bermuda | United States |
| Employees | 44 | N/A |
| Industry | Property-Casualty Insurers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.3M | 70.6M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | KG | INKT |
|---|---|---|
| Price | $11.27 | $12.50 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | 4.7K | ★ 38.0K |
| Earning Date | 05-15-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.38 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.07 | $6.80 |
| 52 Week High | $31.45 | $76.00 |
Technical Indicators
Market Signals| Indicator | KG | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 46.23 | 52.49 |
| Support Level | $10.63 | $10.82 |
| Resistance Level | $12.30 | $12.45 |
| Average True Range (ATR) | 0.75 | 0.83 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 13.57 | 45.36 |
Price Performance
Historical ComparisonAbout KG Kestrel Group Ltd.
Kestrel Group Ltd specializes in providing fronting services to insurance program managers, MGAs, reinsurers, and reinsurance brokers with two reportable segments: Program Services and Legacy Reinsurance. The Group facilitates insurance transactions utilizing its management contracts with four insurance carriers. Its line business includes casualty, workers' compensation, catastrophe-exposed property, and non-catastrophe-exposed property, with diverse risk durations, sizes, and product types.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.